Chimeric RNA molecules generated by trans-splicing
US6013487A · kind A · utility
Inventor
Key dates
| Filing date | Dec 13, 1996 |
| Grant date | Jan 11, 2000 |
| Priority date | — |
| Expiry date | Dec 13, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/445
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The molecules and methods of the present invention provide a means for in vivo production of a therapeutic molecule in a selected subset of cells. The pre-therapeutic molecules of the invention are substrates for a trans-splicing reaction between the pre-therapeutic molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides an active therapeutic RNA which is functional as RNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or a toxin which causes killing of the specific cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.